Volume 9, Number 7—July 2003
Research
Acute Flaccid Paralysis and West Nile Virus Infection
James J. Sejvar*
, A. Arturo Leis†, Dobrivoje S. Stokic†, Jay A. Van Gerpen‡, Anthony A. Marfin*, Risa Webb§, Maryam B. Haddad*, Bruce C. Tierney*, Sally A. Slavinski§, Jo Lynn Polk†, Victor Dostrow†, Michael Winkelmann†, and Lyle R. Petersen*
, A. Arturo Leis†, Dobrivoje S. Stokic†, Jay A. Van Gerpen‡, Anthony A. Marfin*, Risa Webb§, Maryam B. Haddad*, Bruce C. Tierney*, Sally A. Slavinski§, Jo Lynn Polk†, Victor Dostrow†, Michael Winkelmann†, and Lyle R. Petersen*
Table 4
Clinical characteristics of patients with West Nile virus–associated acute flaccid paralysis compared with patients with typical Guillain-Barré syndrome (25–27)a
| Characteristic | West Nile virus–associated flaccid paralysis | Guillain-Barré syndrome |
|---|---|---|
| Timing of onset |
Acute phase of infection |
1–8 weeks after acute infection |
| Fever and leukocytosis |
Present |
Absent |
| Weakness distribution |
Asymmetric; occasional monoplegia |
Generally symmetric; proximal and distal muscles |
| Sensory symptoms |
Absence of numbness, paresthesias, or sensory loss; occasional myalgias |
Painful distal paresthesias and sensory loss |
| Bowel/bladder involvement |
Often present |
Rare |
| Concurrent encephalopathy |
Often present |
Absent |
| CSF profile |
Pleocytosis and elevated protein |
No pleocytosis; elevated protein (albuminocytologic dissociation) |
| Electrodiagnostic features | Anterior horn cell/motor axon: reduced/absent CMAPs, preserved SNAPs; asymmetric denervation | Demyelination: marked slowing of conduction velocity; conduction block, temporal dispersion; reduced SNAPs |
aCSF, cerebrospinal fluid; CMAPs, compound muscle action potentials; SNAPSs, sensory nerve action potentials.
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.